Alzheimer's Researchers Release Free Apps to Track Memory and Cognition
Margaretta Colangelo
Leading AI Analyst | Speaker | Writer | AI Newsletter 56,800+ subscribers
Alzheimer's Disease Researchers at California based Leucadia Therapeutics released a panel of eight apps today to help people track memory and cognition.?The new apps are?ProCogny Memory Tracker, Infinite Mahjong, Iconic Sudoku, Word Recall, Connectors, Image Recall, Pattern Busters, and Speed Demon. The ProCogny Memory Tracker includes a non-clinical version of the proprietary Leucadia Memory Test. There are many digital trackers available to count?steps and other measures of physical activity, but few apps track memory and cognitive function.?The apps include games and puzzles that exercise different?facets of memory such as word recall, reasoning, alternating tasks, matching, object?recognition, pattern recognition, and spatiotemporal memory. The apps are available on Apple’s App Store and Google Play in 22 languages.
Age-associated memory decline is more pronounced in people who develop cognitive impairment and Alzheimer’s disease. Neuroscientists believe that maintaining good memory recall is influenced by diet, exercise, and mental stimulation.?Scientists at Leucadia?Therapeutics used Deep Learning to develop a sophisticated diagnostic algorithm to assess a person's likelihood of developing Alzheimer's. This non-invasive method uses CT scans,?Leucadia's Memory Test, and other measures to help predict risk of developing Alzheimer’s years before cognitive impairment develops.
Leucadia’s team developed this game-based platform to assess memory and cognition of?participants in their Project Cribrose clinical study. The study participants liked the Leucadia Memory Test so much?that the team combined the test with in-house AI and?their ProCogny Memory Tracker to make it available to the public. Users can take?screenshots of their results and share them. Daily Brain?Boosts are rotating collections of mini-puzzles tailored to focus on areas that users had?problems with in the Leucadia?Memory Test.
Download The Apps
ProCogny Memory Tracker, Infinite Mahjong, Iconic Sudoku, Word Recall, Connectors, Image Recall, Pattern Busters, and Speed Demon for mobile phones and tablets are available on Apple’s App Store and Google Play.
ProCogny Memory Tracker is available on Apple’s App Store and Google?Play
Project Cribrose Clinical Study
Leucadia Therapeutics is conducting a 2,000 person clinical study called Project Cribrose . During the study, participants sit for a 20 second CT scan and undergo a battery of cognitive tests developed by Leucadia Therapeutics. The study will produce data for deep learning analysis of behavioral and morphological changes that may provide reliable biomarkers for pending Alzheimer’s disease. Project Cribrose is a collaboration with Neurosurgeons at Arrowhead Regional Medical Center. The study design has been reviewed and approved by Arrowhead Regional Medical Center’s Institutional review board (ARMC IRB #19-11).
Leucadia's Patented Arethusta? Technology
Pharmaceutical companies have invested over $30 billion dollars in a series of high-profile clinical trials for Alzheimer’s disease. Even after all of this money and effort, not a single drug has been developed that can stop or even slow its relentless progression. Led by Founder and CEO Doug Ethell, PhD, Leucadia Therapeutics looks at Alzheimer’s disease in a whole new way. They assembled an amazing team to focus on curing Alzheimer’s disease.?Their mission driven team discovered a major trigger for Alzheimer’s disease pathology and developed a patented strategy to correct that condition.
Leucadia developed a treatment to correct this condition at the cribriform plate, a porous bony structure that becomes occluded as we age. They developed a patented implantable device called Arethusta that repairs the root cause of this pathology and restores?cerebrospinal fluid?flow across the?cribriform plate, improving the clearance of toxic metabolites from the earliest regions of the brain to be affected by Alzheimer's disease. This unique and compelling approach could potentially predict, halt, and cure Alzheimer's disease. The device works in a similar way to the way that they lymphatic system clears toxins from the rest of the body. Clinical trials on Arethusta? are slated to begin in 2022.?
Subscribe and Comment
I'm interested in your feedback - please leave your comments. To subscribe please click the link at the top of this article.
Copyright ? 2021 Margaretta Colangelo. All Rights Reserved.
This article was written by?Margaretta Colangelo. ?Margaretta is a leading AI analyst based in San Francisco. She serves on the advisory board of the AI Precision Health Institute at the University of Hawai?i?Cancer Center.?
Twitter?@realmargaretta
Founder @ Modal <> AI | Automated Compliance & Oversight | Increase Quality & Reduce cost of error
3 年While such apps have their use, the abstract memory games approach don't transfer into real life. I.e. validation assessments obtained are only tested and valid in the game world as well -- and they don't say anything about a persons capabilities in the real world, .e.g. activities of daily living. Transferring test results to the real world is non-trivial and requires complex studies dedicated (3 leg) studies ... I used to work in this area as a, so called, serious game developer for people living with moderate AD [1] as part of an Israeli chief scientist funded project/venture. And our pilot was just a first tiny step in the right direction ... It was a great research project in terms of the impact we could make, and the team i was part of. [1] https://pubmed.ncbi.nlm.nih.gov/28760730/ Designing Serious Computer Games for People With Moderate and Advanced Dementia: Interdisciplinary Theory-Driven Pilot Study
Medical Consultant
3 年Thank you for posting!
Innovation - User-centered design - Health
3 年Thanks for that innovation! I dowlaoded the app but can’t open it; a message saying ??now loading?? stays on my screen without any progression. Anyone experimented a similiar issue or knows how to fix it?
Congrats Doug and team, your hypohesis on the cause of AD striked me when I attended a presentation few years ago. Glad to see a new approach for AD reaching clinical stage. Best luck!
Investor Relations @ Gilmartin Group
3 年So cool! I downloaded ProCogny.